NASDAQ:RARE Ultragenyx Pharmaceutical (RARE) Stock Price, News & Analysis $15.65 -0.30 (-1.88%) Closing price 04:00 PM EasternExtended Trading$15.68 +0.03 (+0.16%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ultragenyx Pharmaceutical Stock (NASDAQ:RARE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get RARE alerts:Sign Up Key Stats Today's Range$15.49▼$15.9450-Day Range$12.88▼$26.5352-Week Range$12.73▼$39.89Volume1.79 million shsAverage Volume3.89 million shsMarket Capitalization$1.54 billionP/E RatioN/ADividend YieldN/APrice Target$33.65Consensus RatingHold Company Overview Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs. Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders. The company also markets Yorvipath (palopegteriparatide) for adults with hypoparathyroidism in the United States. Its pipeline includes investigational treatments for rare skeletal, metabolic, neuromuscular and genetic diseases, including potential gene therapies. Founded in 2010, Ultragenyx is headquartered in Novato, California, and serves patients and healthcare providers through commercial operations in the United States and selected international markets. The company was founded by Emil Kakkis, a physician and rare-disease drug developer who serves as its president and chief executive officer. Ultragenyx has also developed partnerships and licensing arrangements to support the global development and commercialization of its therapies.AI Generated. May Contain Errors. Read More Ultragenyx Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreRARE MarketRank™: 3.11010517907 of 5 starsUltragenyx Pharmaceutical scored higher than 62% of companies evaluated by MarketBeat, and ranked 264th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingUltragenyx Pharmaceutical has received a consensus rating of Hold. The company's average rating score is 2.45, and is based on 1 strong buy rating, 9 buy ratings, 11 hold ratings, and 1 sell rating.Upside PotentialUltragenyx Pharmaceutical has a consensus price target of $33.65, representing about 115.0% upside from its current price of $15.65.Amount of Analyst CoverageUltragenyx Pharmaceutical has been the subject of 20 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ultragenyx Pharmaceutical's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($3.91) to ($0.27) per share.Read more about Ultragenyx Pharmaceutical's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.77% of the float of Ultragenyx Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverUltragenyx Pharmaceutical has a short interest ratio ("days to cover") of 3.13, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ultragenyx Pharmaceutical has recently increased by 22.80%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUltragenyx Pharmaceutical does not currently pay a dividend.Dividend GrowthUltragenyx Pharmaceutical does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.56 News SentimentUltragenyx Pharmaceutical has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Ultragenyx Pharmaceutical this week, compared to 10 articles on an average week.Search InterestOnly 17 people have searched for RARE on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Ultragenyx Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ultragenyx Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $127,561.00 in company stock.Percentage Held by Insiders5.20% of the stock of Ultragenyx Pharmaceutical is held by insiders.Percentage Held by Institutions97.67% of the stock of Ultragenyx Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ultragenyx Pharmaceutical's insider trading history. Receive RARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RARE Stock News HeadlinesUltragenyx Pharmaceutical (RARE) Receives a Buy from Piper SandlerOctober 23 at 12:50 PM | theglobeandmail.comUltragenyx Pharmaceutical (NASDAQ:RARE) Stock: Insider Howard Horn Sells 7,066 SharesOctober 21 at 4:23 AM | americanbankingnews.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.October 23 at 1:00 AM | Base Camp Trading (Ad)Insider Selling: Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells 7,066 Shares of StockOctober 20 at 4:22 AM | insidertrades.comUltragenyx Pharmaceutical Enters Settlement With Navinta Over DojolviOctober 19, 2026 | finance.yahoo.comUltragenyx, Baylor Reach Settlement on DOJOLVI PatentsOctober 19, 2026 | tipranks.comUltragenyx Pharmaceutical (RARE) Receives a New Rating from a Top AnalystOctober 16, 2026 | theglobeandmail.comUltragenyx Pharmaceutical to Sell Priority Review Voucher for $203MOctober 14, 2026 | marketwatch.comSee More Headlines RARE Stock Analysis - Frequently Asked Questions How have RARE shares performed this year? Ultragenyx Pharmaceutical's stock was trading at $23.00 on January 1st, 2026. Since then, RARE stock has decreased by 32.0% and is now trading at $15.65. How were Ultragenyx Pharmaceutical's earnings last quarter? Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) posted its earnings results on Tuesday, August, 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($1.22) by $0.32. Ultragenyx Pharmaceutical's revenue was up 28.5% on a year-over-year basis. Read the conference call transcript. When did Ultragenyx Pharmaceutical IPO? Ultragenyx Pharmaceutical (RARE) raised $112 million in an initial public offering on Friday, January 31st 2014. The company issued 5,760,369 shares at $19.00-$20.00 per share. Who are Ultragenyx Pharmaceutical's major shareholders? Ultragenyx Pharmaceutical's top institutional investors include Assenagon Asset Management S.A. (0.48%), Pinnacle Associates Ltd. (0.16%), Versant Capital Management Inc and Sterling Capital Management LLC. Insiders that own company stock include Emil D Kakkis, Thomas Richard Kassberg, Eric Crombez, John Richard Pinion, Karah Herdman Parschauer, Erik Harris, Howard Horn, Theodore Alan Huizenga, Shehnaaz Suliman, Corazon (Corsee) D Sanders and Matthew K Fust. View institutional ownership trends. How do I buy shares of Ultragenyx Pharmaceutical? Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ultragenyx Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ultragenyx Pharmaceutical investors own include NVIDIA (NVDA), Micron Technology (MU), Tesla (TSLA), Advanced Micro Devices (AMD), Intel (INTC), Broadcom (AVGO) and Netflix (NFLX). Company Calendar Last Earnings8/04/2026Today10/23/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 RARE's financial health is in the Red zone, according to TradeSmith. RARE has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RARE CIK1515673 Webwww.ultragenyx.com Phone(415) 483-8800Fax415-483-8810Employees1,371Year Founded2010Price Target and Rating Average Price Target for Ultragenyx Pharmaceutical$33.65 High Price Target$90.00 Low Price Target$16.00 Potential Upside/Downside+115.0%Consensus RatingHold Rating Score (0-4)2.45 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)($5.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$575 million Net Margins-81.79% Pretax Margin-81.18% Return on EquityN/A Return on Assets-44.40% Debt Debt-to-Equity RatioN/A Current Ratio1.73 Quick Ratio1.56 Sales & Book Value Annual Sales$673 million Price / Sales2.29 Cash FlowN/A Price / Cash FlowN/A Book Value($0.83) per share Price / Book-18.86Miscellaneous Outstanding Shares98,590,000Free Float93,462,000Market Cap$1.54 billion OptionableOptionable Beta0.35 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:RARE) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
